特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
956656

腎臓がん治療と診断の世界市場:2019年-2028年

Global Kidney Cancer Therapeutics and Diagnostics Market Forecast 2019-2028

出版日: | 発行: Inkwood Research | ページ情報: 英文 224 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.49円
腎臓がん治療と診断の世界市場:2019年-2028年
出版日: 2020年09月04日
発行: Inkwood Research
ページ情報: 英文 224 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の腎臓がん治療と診断の市場規模は、2019年から2028年まで5.52%のCAGRで成長を続けると予測されています。市場拡大の原動力となるのは、低侵襲プロセスの利用拡大、 調査開発費の増加、腎臓がん患者の増加などの要因です。

早期診断の普及拡大に伴ってがんの有病率が増加しており、2020年には世界で腎臓がんの症例が22%増加するとの予測もあります。腎臓がんはいくつかの合併症と関連しているため、早期の診断と治療が必要です。リキッドバイオプシーをはじめとする最近の技術的な進歩は、腎臓がん診断の需要を促すと見られています。

当レポートは、世界の腎臓がん治療と診断の市場を調査したもので、市場の力学、がんの種類別、コンポーネント別、地域別の分析、企業プロファイルなどの情報を提供しています。

目次

第1章 調査範囲と調査手法

  • 調査目的
  • 調査範囲
  • 調査手法
  • 前提と制限

第2章 エグゼクティブサマリー

  • 市場規模の推計
  • 市場概要

第3章 市場の力学

  • 市場の定義
  • 主な成長促進要因
    • 腎臓がん症例の増加傾向
    • 最小限の侵襲的プロセスの利用拡大
    • 研究開発費の増加
  • 主な制約
    • 腎臓がん治療と診断の高額な費用
    • 腎臓がん治療薬の臨床試験における成功率の低さ
    • 厳しい規制

第4章 主な分析結果

  • ポーターのファイブフォース分析
  • COVID-19の影響
  • 市場機会マトリクス
  • ベンダー各社の勢力図
  • 投資に関する重要な考察

第5章 がんの種類別の市場

  • 明細胞RCC
  • 乳頭RCC
  • 嫌色素細胞RCC
  • 尿路上皮がん/移行上皮がん
  • その他

第6章 コンポーネント別の市場

  • 医薬品
    • 治療クラス別の医薬品
    • 薬理クラス別の医薬品
  • 診断
    • 画像検査
    • バイオプシー
    • 血液検査
    • その他

第7章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • ロシア
    • ベルギー
    • ポーランド
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリアとニュージーランド
    • タイ
    • インドネシア
    • ベトナム
    • その他
  • その他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第8章 企業プロファイル

  • ABBOTT LABORATORIES
  • AMGEN INC
  • BAYER AG
  • BECTON, DICKINSON AND COMPANY (BD)
  • BRISTOL-MYERS SQUIBB COMPANY
  • EXELIXIS
  • F. HOFFMANN-LA ROCHE
  • MERCK & CO INC
  • MERCK KGAA
  • NOVARTIS INTERNATIONAL AG
  • NXSTAGE MEDICAL INC
  • PFIZER INC
  • SEATTLE GENETIC
図表

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS
  • TABLE 2: RISK FACTORS DEVELOPING KIDNEY CANCER
  • TABLE 3: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 4: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 5: GLOBAL CLEAR CELL RCC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 6: GLOBAL CLEAR CELL RCC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 7: GLOBAL PAPILLARY RCC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 8: GLOBAL PAPILLARY RCC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 9: GLOBAL CHROMOPHOBE RCC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 10: GLOBAL CHROMOPHOBE RCC MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 11: GLOBAL UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 12: GLOBAL UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 13: GLOBAL OTHER KIDNEY CANCERS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 14: GLOBAL OTHER KIDNEY CANCERS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 15: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 16: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 17: GLOBAL DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 18: GLOBAL DRUGS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 19: GLOBAL THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 20: GLOBAL THERAPEUTIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 21: GLOBAL TARGETED THERAPY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 22: GLOBAL TARGETED THERAPY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 23: GLOBAL IMMUNOTHERAPY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 24: GLOBAL IMMUNOTHERAPY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 25: GLOBAL OTHER THERAPEUTIC CLASS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 26: GLOBAL OTHER THERAPEUTIC CLASS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 27: GLOBAL PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 28: GLOBAL PHARMACOLOGIC CLASS DRUGS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 29: GLOBAL ANGIOGENESIS INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 30: GLOBAL ANGIOGENESIS INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 31: GLOBAL MTOR INHIBITORS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 32: GLOBAL MTOR INHIBITORS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 33: GLOBAL MONOCLONAL ANTIBODIES MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 34: GLOBAL MONOCLONAL ANTIBODIES MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 35: GLOBAL CYTOKINE IMMUNOTHERAPY (IL-2) MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 36: GLOBAL CYTOKINE IMMUNOTHERAPY (IL-2) MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 37: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 38: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 39: GLOBAL DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 40: GLOBAL DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 41: GLOBAL IMAGING TEST MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 42: GLOBAL IMAGING TEST MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 43: GLOBAL BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 44: GLOBAL BIOPSY MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 45: GLOBAL BLOOD TEST MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 46: GLOBAL BLOOD TEST MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 47: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 48: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 49: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 50: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 51: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 52: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 53: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 54: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 55: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 56: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)
  • TABLE 57: REST OF KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 58: REST OF KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2019-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 2: OPPORTUNITY MATRIX
  • FIGURE 3: VENDOR LANDSCAPE
  • FIGURE 4: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CANCER TYPE, IN 2019
  • FIGURE 5: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CLEAR CELL RCC, 2019-2028 (IN $ MILLION)
  • FIGURE 6: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY PAPILLARY RCC, 2019-2028 (IN $ MILLION)
  • FIGURE 7: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY CHROMOPHOBE RCC, 2019-2028 (IN $ MILLION)
  • FIGURE 8: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA, 2019-2028 (IN $ MILLION)
  • FIGURE 9: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY OTHER KIDNEY CANCERS, 2019-2028 (IN $ MILLION)
  • FIGURE 10: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY COMPONENT, IN 2019
  • FIGURE 11: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DRUGS, 2019-2028 (IN $ MILLION)
  • FIGURE 12: GLOBAL THERAPEUTIC DRUG CLASS MARKET, BY TARGETED THERAPY, 2019-2028 (IN $ MILLION)
  • FIGURE 13: GLOBAL THERAPEUTIC DRUG CLASS MARKET, BY IMMUNOTHERAPY, 2019-2028 (IN $ MILLION)
  • FIGURE 14: GLOBAL THERAPEUTIC DRUG CLASS MARKET, BY OTHER THERAPEUTIC CLASS, 2019-2028 (IN $ MILLION)
  • FIGURE 15: GLOBAL PHARMACOLOGIC CLASS MARKET, BY ANGIOGENESIS INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 16: GLOBAL PHARMACOLOGIC CLASS MARKET, BY MTOR INHIBITORS, 2019-2028 (IN $ MILLION)
  • FIGURE 17: GLOBAL PHARMACOLOGIC CLASS MARKET, BY MONOCLONAL ANTIBODIES, 2019-2028 (IN $ MILLION)
  • FIGURE 18: GLOBAL PHARMACOLOGIC CLASS MARKET, BY CYTOKINE IMMUNOTHERAPY (IL-2), 2019-2028 (IN $ MILLION)
  • FIGURE 19: GLOBAL KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2019-2028 (IN $ MILLION)
  • FIGURE 20: GLOBAL DIAGNOSTICS MARKET, BY IMAGING TEST, 2019-2028 (IN $ MILLION)
  • FIGURE 21: GLOBAL DIAGNOSTICS MARKET, BY BIOPSY, 2019-2028 (IN $ MILLION)
  • FIGURE 22: GLOBAL DIAGNOSTICS MARKET, BY BLOOD TEST, 2019-2028 (IN $ MILLION)
  • FIGURE 23: GLOBAL DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2019-2028 (IN $ MILLION)
  • FIGURE 24: NORTH AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 25: THE UNITED STATES KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 26: CANADA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 27: EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 28: GERMANY KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 29: THE UNITED KINGDOM KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 30: FRANCE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 31: ITALY KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 32: RUSSIA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 33: BELGIUM KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 34: POLAND KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 35: REST OF EUROPE KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 36: ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 37: CHINA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 38: JAPAN KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 39: INDIA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 40: SOUTH KOREA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 41: AUSTRALIA & NEW ZEALAND KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 42: THAILAND KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 43: INDONESIA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 44: VIETNAM KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 45: REST OF ASIA PACIFIC KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 46: REST OF KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 47: LATIN AMERICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
  • FIGURE 48: MIDDLE EAST & AFRICA KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS MARKET, 2019-2028 (IN $ MILLION)
目次
Product Code: 33617

KEY FINDINGS

The global kidney cancer therapeutics and diagnostics market is projected to register a CAGR of 5.52% during the forecast period, 2019-2028. The factors propelling the growth of the market are estimated to be the rising usage of minimally invasive processes, increasing research & development expenditure, and the growing prevalence of kidney cancer cases.

MARKET INSIGHTS

There is an increasing prevalence of cancer, along with the rising adoption of early diagnosis. Some estimations suggest that there will be a 22% increase in kidney cases across the globe in 2020. It is necessary to diagnose and treat kidney cancer at the earliest, since it is associated with several comorbidities. Recent advancements like the liquid biopsy technique are projected to result in healthy demand for kidney cancer diagnosis.

There is an emphasis on using minimally-invasive techniques in surgical procedures. There has been an increase in the use of the minimally-invasive catheter-based endovascular procedure to regulate hypertension. This has resulted in the growing adoption of kidney cancer treatment devices. These devices reduce cardiometabolic risks. They also aid in minimizing hospital stay, since the procedure and the necessary processes do not take more than six hours. This restricts direct and indirect hospitalization costs. Thus, rising minimally-invasive processes drive market growth. However, the high costs associated with the treatment and diagnosis, are projected to restrain the market growth.

REGIONAL INSIGHTS

The analysis of the geographical division of the global kidney cancer therapeutics and diagnostics market includes the assessment of Asia Pacific, Europe, North America, and the rest of the world. North America dominated the global market in 2019. The well-developed healthcare infrastructure and the presence of major companies are influencing the market growth prospects of the region.

COMPETITIVE INSIGHTS

As per estimations, there will be intense competition between the well-established cancer therapeutics manufacturers. Some of the established players in the market include Bayer AG, Amgen Inc, Abbott Laboratories, Becton, Dickinson and Company (BD), etc.

Our report offerings include:

  • Explore key findings of the overall market
  • Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
  • Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
  • Market Segmentation cater to a thorough assessment of key segments with their market estimations
  • Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
  • Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
  • Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
  • Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. MARKET DEFINITION
  • 3.2. KEY DRIVERS
    • 3.2.1. GROWING PREVALENCE OF KIDNEY CANCER CASES
    • 3.2.2. INCREASING USAGES OF MINIMALLY INVASIVE PROCESSES
    • 3.2.3. SURGING RESEARCH AND DEVELOPMENT EXPENDITURE
  • 3.3. KEY RESTRAINTS
    • 3.3.1. HIGH COSTS ASSOCIATED WITH THE TREATMENT AND DIAGNOSIS OF KIDNEY CANCER
    • 3.3.2. LOW RATE OF SUCCESS IN THE CLINICAL TRIALS OF KIDNEY CANCER DRUGS
    • 3.3.3. STRINGENT REGULATIONS

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. IMPACT OF COVID-19 ON KIDNEY CANCER THERAPEUTICS AND DIAGNOSTICS
  • 4.3. OPPORTUNITY MATRIX
  • 4.4. VENDOR LANDSCAPE
  • 4.5. KEY INVESTMENT INSIGHT

5. MARKET BY CANCER TYPE

  • 5.1. CLEAR CELL RCC
  • 5.2. PAPILLARY RCC
  • 5.3. CHROMOPHOBE RCC
  • 5.4. UROTHELIAL CARCINOMA/TRANSITIONAL CELL CARCINOMA
  • 5.5. OTHER KIDNEY CANCERS

6. MARKET BY COMPONENT

  • 6.1. DRUGS
    • 6.1.1. DRUGS BY THERAPEUTIC CLASS
      • 6.1.1.1. TARGETED THERAPY
      • 6.1.1.2. IMMUNOTHERAPY
      • 6.1.1.3. OTHER THERAPEUTIC CLASS
    • 6.1.2. DRUGS BY PHARMACOLOGIC CLASS
      • 6.1.2.1. ANGIOGENESIS INHIBITORS
      • 6.1.2.2. MTOR INHIBITORS
      • 6.1.2.3. MONOCLONAL ANTIBODIES
      • 6.1.2.4. CYTOKINE IMMUNOTHERAPY (IL-2)
  • 6.2. DIAGNOSTICS
    • 6.2.1. IMAGING TEST
    • 6.2.2. BIOPSY
    • 6.2.3. BLOOD TEST
    • 6.2.4. OTHER DIAGNOSTICS

7. GEOGRAPHICAL ANALYSIS

  • 7.1. NORTH AMERICA
    • 7.1.1. THE UNITED STATES
    • 7.1.2. CANADA
  • 7.2. EUROPE
    • 7.2.1. GERMANY
    • 7.2.2. THE UNITED KINGDOM
    • 7.2.3. FRANCE
    • 7.2.4. ITALY
    • 7.2.5. RUSSIA
    • 7.2.6. BELGIUM
    • 7.2.7. POLAND
    • 7.2.8. REST OF EUROPE
  • 7.3. ASIA PACIFIC
    • 7.3.1. CHINA
    • 7.3.2. JAPAN
    • 7.3.3. INDIA
    • 7.3.4. SOUTH KOREA
    • 7.3.5. AUSTRALIA & NEW ZEALAND
    • 7.3.6. THAILAND
    • 7.3.7. INDONESIA
    • 7.3.8. VIETNAM
    • 7.3.9. REST OF ASIA PACIFIC
  • 7.4. REST OF WORLD
    • 7.4.1. LATIN AMERICA
    • 7.4.2. MIDDLE EAST & AFRICA

8. COMPANY PROFILES

  • 8.1. ABBOTT LABORATORIES
  • 8.2. AMGEN INC
  • 8.3. BAYER AG
  • 8.4. BECTON, DICKINSON AND COMPANY (BD)
  • 8.5. BRISTOL-MYERS SQUIBB COMPANY
  • 8.6. EXELIXIS
  • 8.7. F. HOFFMANN-LA ROCHE
  • 8.8. MERCK & CO INC
  • 8.9. MERCK KGAA
  • 8.10. NOVARTIS INTERNATIONAL AG
  • 8.11. NXSTAGE MEDICAL INC
  • 8.12. PFIZER INC
  • 8.13. SEATTLE GENETIC
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.